AbbVie
Global biopharmaceutical company developing medicines
Medical Director - Neuroscience, Global Patient Safety
Hybrid role; some on-site days in North Chicago, Illinois.
About the job
- MD / DO with 2+ years of residency with patient management experience
- 2-5 years of Pharmacovigilance / Clinical Development experience in the pharmaceutical industry.
- Fluency, both written and oral, in English.
- Understanding and application of the pharmacology, chemistry and non-clinical toxicology to effectively conduct safety surveillance.
- Responsible for safety surveillance for pharmaceutical / biological / drug –device combination products
- Lead, oversee, and set the strategy for key pharmacovigilance documents, including but not limited to, medical safety assessments, regulatory responses, risk management plans, periodic safety reports (DSURs, PBRERs/PSURs, PADERs), etc.
- Lead and oversee safety surveillance and pharmacovigilance activities for products in clinical development and marketed products, applying current regulatory guidance as appropriate
- Analyze and interpret aggregate safety data and communicate these analysis and interpretation to cross-functional teams and regulatory authorities.
- Effectively and independently write, review, and present technical documents .
- Responsible for implementing risk management strategies for assigned products.
- Proactively engaging, inspiring, coaching and mentoring team and colleagues.
- Master Public Health is preferred in addition to MD / DO, not required.
- Effectively analyze and guide analysis of clinical data and epidemiological information.
- Effectively present recommendations / opinions in group environment both internally and externally.
- Write, review and provide input on technical documents.
- Work collaboratively and lead cross-functional teams.
- Ability to lead cross-functional teams in a collaborative environment.
- Evaluate and make independent decisions. Ability to work effectively in the situation of uncertainty and complexity, ability to multitask.
About the company
AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.
Company Size
10,001+
Company Stage
IPO
Headquarters
North Chicago, Illinois
Founded
1888
Get referred to AbbVie
See people who can refer or advise you
Simplify's Take
What believers are saying
- RINVOQ gained European approval for juvenile idiopathic arthritis on September 22, 2026.
- July 2026 European approval expanded RINVOQ in severe alopecia areata.
- Etentamig delivered 74% response rates in September 2026 myeloma data.
What critics are saying
- Humira sales fell 36.1% in July 2026, exposing lingering erosion.
- Apogee dilutes 2026 EPS by $0.14, then $0.46 in 2027.
- Rinvoq and Skyrizi face 2033 patent pressure despite current settlements.
What makes AbbVie unique
- Skyrizi and Rinvoq anchor AbbVie’s post-Humira immunology franchise in 2026.
- Apogee acquisition adds zumilokibart and asthma biology after September 3, 2026.
- Iambic collaboration broadens AI discovery across immunology, neuroscience, and oncology.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Flexible Work Hours
Professional Development Budget
Growth & Insights and Company News
6 month growth
↑ 5%1 year growth
↑ 5%2 year growth
↑ 5%ADARx Pharmaceuticals has priced its initial public offering of 21.875 million shares between $15.00 and $17.00 per share, according to an SEC filing. The San Diego-based late-clinical stage biotechnology company has applied to list on Nasdaq under the ticker "ADRX". AbbVie has agreed to purchase shares in a concurrent private placement that would give it approximately 4.9% ownership of ADARx's outstanding stock. Underwriters have a 30-day option to purchase up to 3.28 million additional shares. The company estimates net proceeds of approximately $397.1 million, or $445.9 million if underwriters exercise their option in full, assuming a $16.00 share price. Proceeds will fund clinical trial development and general corporate purposes.
AbbVie and Iambic Therapeutics have entered into a multi-year collaboration to accelerate AI-driven drug discovery in immunology, neuroscience, and oncology. The partnership will combine Iambic's molecular superintelligence platform with AbbVie's therapeutic expertise to develop small molecule therapies with first-in-class and best-in-class potential. The collaboration will utilise Enchant v3, Iambic's next-generation multimodal transformer model trained on over 6,000 molecular properties. This technology is designed to optimise candidate properties simultaneously, reducing drug discovery timelines whilst improving success rates. Under the agreement, Iambic will receive an upfront payment and is eligible for success-based milestone payments and tiered royalties on net sales from products generated through the collaboration. The partnership aims to accelerate the discovery process and deliver breakthrough medicines to patients more quickly.
Acquisition adds a potential first-in-class in vivo targeted lipid nanoparticle (tLNP) anti-CD19 CAR-T therapy candidate for B cell-mediated autoimmune diseases as well as a proprietary tLNP...
Acquisition deepens AbbVie's robust immunology pipeline with diverse assets targeting dermatologic, respiratory and other inflammatory and immunological diseases Apogee's lead asset, zumilokibart,...
September 18, 2026 AbbVie highlights new real-world data supporting the effectiveness of VRAYLAR(R)(cariprazine) at Psych Congress 2026. * New data from prospective real-world studies of VRAYLAR showed meaningful improvements in depressive symptoms, functioning and quality of life among adults living with major depressive disorder (MDD) and bipolar I (BP-I) depression * These findings provide additional evidence that the benefits observed with VRAYLAR in clinical trials can also be achieved in routine practice, where patients often have more complex treatment needs NORTH CHICAGO, Ill., Sept. 18, 2026 /PRNewswire/ - AbbVie (NYSE: ABBV) today presented new VRAYLAR(R)(cariprazine) data at Psych Congress 2026 in New Orleans, including results from two prospective real-world observational studies in major depressive disorder (MDD) and bipolar I disorder (BP-I). The findings reinforce that the efficacy established in clinical trials translates to effectiveness in the broader, more clinically complex patient populations healthcare providers treat every day. "Because mood disorders are highly heterogeneous, it is critical to evaluate treatments in real-world settings where care is delivered every day," said Mudra Kapoor, M.D., vice president, global medical affairs, AbbVie. "These prospective studies provide additional evidence that VRAYLAR can help patients achieve meaningful improvements in depressive symptoms, functioning and other patient-centered outcomes in routine clinical practice." In the real-world BP-I depression study, CReW BP-I, patients treated with VRAYLAR experienced significant improvements in depressive symptoms as well as outcomes that affect daily life, including functioning and quality of life, after 12 weeks of treatment in routine clinical practice; the most common adverse events were nausea and dizziness. In ProACt, a real-world study of adjunctive VRAYLAR in MDD, interim findings showed improvements not only in depressive symptoms, but also in outcomes that affect day-to-day life and matter most to patients, including functioning, motivation, energy and anhedonia. In addition to these real-world studies, AbbVie also presented an indirect comparative analysis in MDD, long-term pediatric safety data, and patient preference research evaluating treatment approaches following inadequate antidepressant response. "For clinicians, one of the most important questions is whether the benefits demonstrated in clinical trials hold up in the real world, where patients have unique needs, experiences and treatment journeys," said Andrew J. Cutler, M.D., an author of the ProACt study, Clinical Professor of Psychiatry at SUNY Upstate Medical University and Chief Medical Officer of the Neuroscience Education Institute. "These studies reinforce what has been established in VRAYLAR clinical trials and provide additional confidence that meaningful improvements in symptoms, functioning and patient-reported outcomes can be achieved beyond the controlled environment of a trial. That kind of real-world validation is valuable when making individualized treatment decisions in everyday clinical practice." MDD and BP-I can profoundly affect every aspect of a person's life and often require long-term, comprehensive care. Approximately one in five U.S. adults will experience MDD during their lifetime, and nearly 11 million adults are living with bipolar disorder, yet many continue to experience ongoing symptoms despite available treatments - highlighting persistent unmet treatment needs.